Accounting for unmeasured confounders in treatment response: a comparison of levodopa versus non-levodopa dopaminergic drugs
Objective: To compare short-term levodopa and non-levodopa dopaminergic treatment response in people with Parkinson’s disease (PD) using instrumental variable analysis and linear regression. Background: Treatment…Treatment characterization and decision-making strategy for first-line pharmacological motor symptomatic therapies in Parkinson’s disease
Objective: (1) To characterize motor therapeutic use in the Parkinson’s Progression Markers Initiative (PPMI) early, untreated (de novo) cohort, and (2) to develop an evidence-based…Apomorphine subcutaneous infusion reduces dopaminergic dosage whilst maintaining motor benefits in Parkinson’s disease: A prospective analysis of Thai Apomorphine Registry
Objective: To evaluate a reduction of LED in PD patients who achieve satisfactory motor control with long-term continuous subcutaneous apomorphine infusion (CSAI) Background: Apomorphine is…Quality of Life Study of Patients Living with Parkinson’s Disesae in Sub-Saharan Africa
Objective: The objective is to assess the quality of life of patients with Parkinson's disease followed in Senegal. Background: Parkinson's disease is a neurodegenerative disease,…Trends in first line therapy for PD in Wales: A 16 year observational study
Objective: To examine the changes in first line therapy of newly diagnosed Parkinson’s patients between 2000 and 2016 in Wales. Background: There have been several…Parkinson’s disease polygenic risk score is not associated with impulse control disorders: a longitudinal study
Objective: To examine the relationship between a polygenic risk score (GRS) associated with Parkinson’s disease (PD) and impulse control disorders (ICDs) in PD. Background: Genome…Impulse control disorders and (romantic) jealousy in Parkinson’s disease: a patients’ vs. partners’ perspective
Objective: To compare self-reported symptoms of (romantic) jealousy and impulse control disorders (ICD) in Parkinson’s disease (PD) patients to those reported by their partners. Background:…Longitudinal analysis of the relation between trajectories of dopaminergic agonists use and BMI in Parkinson’s disease
Objective: To describe the longitudinal relation between dopaminergic agonists (DA) use and change of BMI in a longitudinal cohort of PD patients followed annually up…Long-term apomorphine infusion (APO) users versus short-term APO users: What is the reason to discontinue therapy? A multi-centre study
Objective: To evaluate the long-term efficacy of APO in PD patients treated at two specialist centres in Spain and Thailand, and to determine the reasons…Predictors of refractory impulse control disorder to dopamine agonists substitution therapy in Parkinson’s disease patients
Objective: This study was aimed to investigate a predictive factor of refractory impulse control disorder (ICD) in patients with Parkinson’s disease (PD) who participated in…
- « Previous Page
- 1
- …
- 4
- 5
- 6
- 7
- 8
- …
- 15
- Next Page »